ITGAM and neoplasm: Frequency of CD11b+Gr-1+ cells was considered as an important factor to promote tumor progression and tumor cell resistance, and as an independent factor to evaluate the efficacy and prognosis of anti-tumor therapy (Ai et al., 2018).